NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Kingsman Wealth Management Acquires Additional Stake in Biopol Chemicals

Key Highlights:

  • Kingsman Wealth Management acquired an additional 0.7% equity stake in Biopol Chemicals via open market transactions on March 13.
  • Biopol Chemicals shares rallied 3.39% to Rs 100.65 on the National Stock Exchange following a 3.61% decline in the previous session.

Details of Transaction:

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

  • Kingsman Wealth Management bought 80,400 equity shares (equivalent to 0.74% of paid-up equity) in Biopol Chemicals at Rs 96.99 per share.
  • D V Investments sold 78,000 shares at Rs 97 per share.
  • As of February 12, Kingsman Wealth Management already held a 5.55% stake (6 lakh shares) in Biopol Chemicals.
  • On March 12, Kingsman Wealth Management also acquired a 1.21% stake in the company.

Promoter Activity:

  • Mark AB Welfare Trust, promoter of SEPC, sold 1.27 crore equity shares (0.65% stake) in the EPC company at Rs 5.31 per share for Rs 6.76 crore.
  • In the previous session, SEPC promoter offloaded 0.48% (85 lakh shares).

Investor Takeaway

Investors should be aware of potential market movements in Biopol Chemicals following Kingsman Wealth Management's expanded stake.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.